Abstract
Platelet-activating factor (PAF) is a potent inflammatory mediator which is released by various inflammatory cells and produced by certain tissues, including the kidney. PAF has been shown to increase glomerular permeability to protein and to decrease glomerular filtration rate (GFR) by contracting mesangium. On the basis of these observations, it has been suspected that PAF may play a role as mediator of glomerular damage in glomerular nephritis. To examine this possibility, we studied the effects of a specific PAF antagonist, R-75,317, on the development of an experimental model of anti-glomerular basement membrane (anti-GBM) glomerulonephritis. Glomerulonephritis was initiated by injecting rabbit anti-rat GBM serum into rats. Proteinuria gradually developed after serum injection, plateaued at week 2, and remained at the high level of week 2 throughout the experimental period (6 wk). Chronic treatment with R-75,317 (10 mg/kg/day i.p.) tended to delay the onset of proteinuria and significantly accelerated the recovery phase. Creatinine clearance (Ccr) fell to 40% at week 3. R-75,317 treatment completely prevented this decline of Ccr. Histological changes in this model (glomerular hypertrophy, proliferation of mesangial matrix and interstitial fibrosis) were also ameliorated by the R-75,317 treatment. The results suggest that PAF may play a role in the development of glomerulonephritis and that PAF antagonists could be used in the treatment of human renal disease.
Similar content being viewed by others
Abbreviations
- AA:
-
arachidonic acid
- Ccr:
-
creatinine clearance
- GBM:
-
glomerular basement membrane
- GFR:
-
glomerular filtration rate
- NAG:
-
N-acetyl-β-D-glucosaminidase
- PAF:
-
plateletactivating factor, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine
References
Benveniste, J., Henson, P.M., and Cochrane, C.G. (1972)J. Exp. Med. 136, 1356–1377.
Chignard, M., Le Couedic, J.P., Vargaftig, B.B., and Benveniste, J. (1980)Br. J. Haematol. 46, 455–464.
Camussi, G., Aglietta, M., Coda, R., Bussolino, F., Piacibello, W., and Tetta, C. (1981)Immunology 42, 191–199.
Camussi, G., Tetta, C., Coda, R., Segoloni, G.P., and Vercellone, A. (1984)Kidney Int. 25, 73–81.
Scherf, H., Nies, A.S., Schwertschlag, U., Hughes, M., and Gerber, J.G. (1986)Hypertension 8, 737–741.
Badr, K.F., Deboer, D.K., Takahashi, K., Harris, R.C., Fogo, A., and Jacobson, H.R. (1989)Am. J. Physiol. 256, F35-F43.
Pirotzky, E., Bidault, J., Burtin, C., Gubler, M.C., and Benveniste, J. (1984)Kidney Int. 26, 404–410.
McIntyre, T.M., Zimmerman, G.A., and Prescott, S. (1986)Proc. Natl. Acad. Sci. USA 83, 2204–2209.
Schlondorff, D., Goldwasser, P., Neuwirth, R., Satriano, J.A., and Clay, K.L. (1986)Am. J. Physiol. 250, F1123-F1127.
Unanue, E.R., and Dixon, F.J. (1967)Adv. Immunol. 6, 1–90.
Wilson, C.B., and Dixon, F.J. (1986) inThe Kidney, pp. 800–890, W. B. Saunders Co., Philadelphia.
Nakamura, N., Koike, H., and Oshima, T. (1987) European Patent Appl. EP 87301283.5(870213).
Hammer, D.K., and Dixon, F.J. (1963)J. Exp. Med. 117, 1019–1040.
Silva, F.G., Hoyer, J.R., and Pirani, L. (1984)Lab. Invest. 51, 404–415.
Unanue, E.R., and Dixon, F.J. (1964)J. Exp. Med. 119, 965–982.
Cochrane, C.G., Unanue, E.R., and Dixon, F.J. (1965)J. Exp. Med. 122, 99–116.
Pirotzky, E., Page, C., Morley, J., Bidault, J., and Benveniste, J. (1985)Agents and Actions 16, 17–18.
Perico, N., Delaini, F., Tagliaferri, M., Abbate, M., Cucchi, M., Bertani, T., and Remuzzi, G. (1988)Lab. Invest. 58, 163–171.
Schwertschlag, U.S., Dennis, V.W., Tucker, J.A., and Camussi, G. (1988)Kidney Int. 34, 779–785.
Bertani, T., Livio, M., Macconi, D., Morigi, M., Bisogno, G., Patrono, C., and Remuzzi, G. (1987)Kidney Int. 31, 1248–1256.
Hebert, R.L., Sirois, P., Braquet, P., and Plane, G.E. (1987)Prostaglandins, Leukotrienes Med. 26, 189–202.
Lianos, E.A., Andres, G.A., and Dunn, M.J. (1983)J. Clin. Invest. 72, 1439–1448.
Badr, K.F., Schreiner, G.F., Wasserman, M., and Ichikawa, I. (1988)J. Clin. Invest. 81, 1702–1709.
Weisman, S.M., Felsen, D., and Vaughan Jr., E.D. (1985)J. Pharmacol. Exp. Ther. 235, 10–15.
Author information
Authors and Affiliations
About this article
Cite this article
Miyamoto, M., Koike, H., Sada, T. et al. The effects of R-75,317 on antiglomerular basement membrane glomerulonephritis in rats. Lipids 26, 1316–1319 (1991). https://doi.org/10.1007/BF02536556
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02536556